Granules India has informed that Company’s Gagillapur facility located at Hyderabad, Telangana, India has successfully completed US FDA inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).
The above information is a part of company’s filings submitted to BSE.